PARR THOMAS R,LEHOUX DARIO,MOECK GREGORY,ETIENNE PIERRE
申请号：
NZ59152509
公开号：
NZ591525A
申请日:
2009.08.29
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
591525 Disclosed is the use of oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent for the manufacture of a medicament for the complete and effective treatment of complicated skin and skin structure infection (cSSSI) in a subject, wherein the medicament is formulated to comprise at least about 900 mg of oritavancin, or a pharmaceutically acceptable salt thereof, and be administered to the subject in one dose over the course of therapy to thereby treat the bacterial infection.
